Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.

Articles

Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).

Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

Screening for cognitive impairment among patients with systemic lupus erythematosus (SLE) can be challenging; however, some shorter assessments have shown promise for use in the clinical setting.

Cognitive Impairment Screening in the Clinic for Patients With SLE 

COVID-19 likely does not increase the risk of asthma development in pediatric patients, research suggests. 


COVID-19 Not Associated With Asthma Development in Children

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.

Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Emerging Therapies and Preventive Treatments for Migraine